FDA advises consumers not to use Blue Steel and Hero dietary supplements

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.

As artificial intelligence evolves from a novel technology to commonplace in health care, the pharmacy industry is adapting to its challenges and opportunities.

Alkaptonuria affects approximately 1 in 250,000 to 1 million people in the United States.

From market pressures to regulatory framework, Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, discussed growth in the business of health-system pharmacy and the challenges it has faced.

The new approval is for a first-in-class TRPM8 receptor agonist to stimulate corneal sensory nerves to increase natural tear production.

The replacement therapy is indicated for patients 5 years and older, marking the first approval for an oral solution form of hydrocortisone.